Abeona Therapeutics Inc.
↗Cleveland, Ohio, USA
Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing and manufacturing novel cell and gene therapies for life-threatening rare genetic diseases. The company utilizes proprietary platforms, including its AIM™ AAV vector technology, to create targeted genetic medicines.
Abeona operates a fully integrated, cGMP-compliant manufacturing facility in-house, which supports both clinical and commercial production. Its lead asset, ZEVASKYN (prademagene zamikeracel), is an autologous, cell-based gene therapy developed for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$5M-$10M
Founded:1974
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:NASDAQ
Ticker:ABEO
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Cell therapy, Gene therapy
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Taysha Gene Therapies (Licensing/Inventory purchase for ABO-202)
COMPETITION
Position:Niche Player
Competitors:Miragen Therapeutics
LEADERSHIP
Key Executives:
Vishwas Seshadri - CEO
Joseph Vazzano - CFO
LINKS
Website:abeonatherapeutics.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Abeona Therapeutics Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Abeona Therapeutics Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.